Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
about
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibClinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerationsDasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsMeasuring the symptom burden associated with the treatment of chronic myeloid leukemiaMeasuring symptoms as a critical component of drug development and evaluation in hematological diseasesCritical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.Fluid retention associated with imatinib treatment in patients with gastrointestinal stromal tumor: quantitative radiologic assessment and implications for managementGenetic basis for the increased expression of vacuolar H+ translocating ATPase genes upon imatinib treatment in human lymphoblastoid cells.Management of imatinib-resistant patients with chronic myeloid leukemia.Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia.Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib TherapyThe Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burdenThe matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia.Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysisPrävention und Management kardiovaskulärer Erkrankungen mit Nilotinib
P2860
Q26751285-001CEF10-06FC-40DB-BDF1-75E335641702Q27004032-29716B6B-4A0D-441B-AA8A-503C6DCC4350Q28079372-0BD7A230-13FB-40DB-9955-6E300F3AE4DCQ28689231-CCB9BAB8-C140-424C-B3D2-E76FE40B5335Q33705743-49EFD108-D640-4D5D-8FB1-8FE762710D5CQ34894883-168D5FB7-A67F-4F5D-AA45-42E597E97ECEQ35140171-5D45D459-4CA2-4A70-8AEA-014B8FB13DDCQ36721667-6F5627DF-9BFC-4DB6-BEA0-D58A192EE0C4Q36776423-EF27B6EE-905A-4B56-9A7D-6BCDDACB4D70Q37676310-82329C45-554B-4588-A201-B35611252D47Q37870181-0126D1B6-DD0E-4E7E-A6F1-E06541035007Q39797514-A7BAEB50-4898-4D1E-B5A4-829A41290BCCQ40346616-800426C9-7446-49C8-A5FF-41B3E4B821B9Q41601810-6246AA37-103A-40F4-8F0B-10D68D9CEFBFQ41842515-F7741AD0-5704-4360-A381-A4FC82E17BE3Q42633004-A62D411A-BC41-4BD1-82F2-3762B62B86A3Q43128355-A6DCCBFE-F7DE-4A52-AAF7-8AAF58763009Q43675594-1D4F7EA8-FA35-4630-A1B3-AAEA6EB60C65Q47617369-9BF54147-4FA6-46D3-8292-4726D72680DCQ48082559-D00B3E15-6030-4442-A420-11116C032030Q48170931-46F4A158-DAD3-46CD-A32D-C0CE9BBA56C9Q48210350-15F62541-4198-4A55-BD96-741248C0AA53Q48449111-7E7BF201-07FE-4AD3-B780-579E76ABED65Q57069646-BCEC7EA2-8253-4BE0-846A-2C11118222FEQ58023676-025500C9-93FE-4F37-B057-8CAA36900FC2
P2860
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intolerance to tyrosine kinase ...... ons and clinical implications.
@en
Intolerance to tyrosine kinase ...... ons and clinical implications.
@nl
type
label
Intolerance to tyrosine kinase ...... ons and clinical implications.
@en
Intolerance to tyrosine kinase ...... ons and clinical implications.
@nl
prefLabel
Intolerance to tyrosine kinase ...... ons and clinical implications.
@en
Intolerance to tyrosine kinase ...... ons and clinical implications.
@nl
P2860
P356
P1433
P1476
Intolerance to tyrosine kinase ...... ons and clinical implications.
@en
P2093
Javier Pinilla-Ibarz
Michael J Mauro
P2860
P304
P356
10.1002/CNCR.25648
P407
P577
2010-10-04T00:00:00Z